Coronavirus Update - 09th November 2020

We would like to reassure our customers that as England enters its second national lockdown period, we remain open for business and at full capacity as we have done since the start of this pandemic and fully comply with all government guidance on minimising the risks of COVID-19.

As the situation continues to evolve, we will keep all our customers and stakeholders informed of our activities through this web-page which is updated on a regular basis.

French Tax Authority Grants Arcinova with R&D Organisation Status

Arcinova has been recognised and approved by the French Tax Authorities as an organisation undertaking R&D activities.  This will bestow significant benefits upon any French customers to whom Arcinova provides a service.  The recognition and approval as a ‘R&D organisation’ means that French customers of Arcinova can attract an additional 30% R&D Tax Credit when assessing their tax charge, thus reducing the customers French tax bill.  

The approval covers 2016, 2017 and 2018 and will help to improve Arcinova’s competitive stance as we look to expand further into the French pharmaceutical research sector. 




Discover how Arcinova can help

We provide a fully integrated approach to drug development, speak to our team and discover how we can help you fast forward to market.

GET IN TOUCH